Based in China, the global clinical-stage bio-tech company Clover Biopharmaceuticalsis focusing on innovative biologic therapies, sealed a US$ 43m (RMB 304m) Series B financing.
Lead by Delos Capital and Lapam Capital, along with some help by from Betta Capital, Sichuan Health Care Industry Fund, Beijing Zhongguancun VC and Jinlong Group, brought the combined capital rise to more than $100 million since 2016.
Continued clin....
Tags : Biopharmaceuticals, Series B Funding , $43M raised, clinical-stage,
comments (0)